Regulatory

AbbVie receives EC approval for Aquipta to treat migraine

Pharmaceutical Technology

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

Pain & Anaesthesia

Read full story

pharminent June 3, 2026 (Last updated: June 3, 2026)

Pharmaceutical Technology

AbbVie has received approval from the EC for Aquipta, an oral CGRP receptor antagonist, for the acute treatment of migraine in adults, with or without aura.

Pain & Anaesthesia

Read full story

Related Stories

FDA taps prior knowledge to expedite cell and gene therapy development

FDA Issues Draft Guidance to Help Accelerate Cell and Gene Therapies for Patients

FDA approves AstraZeneca’s Imfinzi-BCG combination for NMIBC therapy

You May Have Missed

FDA taps prior knowledge to expedite cell and gene therapy development

AbbVie receives EC approval for Aquipta to treat migraine

Eli Lilly issues data sharing ultimatum to 340B hospitals

Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug